KALV
Price:
$10.15
Market Cap:
$494.46M
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, ...[Read more]
Industry
Biotechnology
IPO Date
2015-04-09
Stock Exchange
NASDAQ
Ticker
KALV
According to KalVista Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 468.87M. This represents a change of -0.89% compared to the average of 473.10M of the last 4 quarters.
The mean historical Enterprise Value of KalVista Pharmaceuticals, Inc. over the last ten years is 202.14M. The current 468.87M Enterprise Value has changed 23.09% with respect to the historical average. Over the past ten years (40 quarters), KALV's Enterprise Value was at its highest in in the July 2024 quarter at 646.63M. The Enterprise Value was at its lowest in in the March 2016 quarter at -26875873.00.
Average
202.14M
Median
189.44M
Minimum
31.73M
Maximum
432.11M
Discovering the peaks and valleys of KalVista Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 549.03%
Maximum Annual Enterprise Value = 432.11M
Minimum Annual Increase = -66.16%
Minimum Annual Enterprise Value = 31.73M
Year | Enterprise Value | Change |
---|---|---|
2024 | 393.05M | 97.13% |
2023 | 199.39M | -31.01% |
2022 | 289.00M | -33.12% |
2021 | 432.11M | 140.74% |
2020 | 179.49M | -43.00% |
2019 | 314.91M | 549.03% |
2018 | 48.52M | 22.93% |
2017 | 39.47M | 24.39% |
2016 | 31.73M | -66.16% |
2014 | 93.77M | 88.67% |
The current Enterprise Value of KalVista Pharmaceuticals, Inc. (KALV) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
293.81M
5-year avg
298.61M
10-year avg
202.14M
KalVista Pharmaceuticals, Inc.’s Enterprise Value is less than Crinetics Pharmaceuticals, Inc. (4.93B), greater than Theseus Pharmaceuticals, Inc. (138.26M), less than Kura Oncology, Inc. (807.00M), less than Viridian Therapeutics, Inc. (1.42B), less than Replimune Group, Inc. (984.10M), greater than Nuvectis Pharma, Inc. (81.37M), greater than Lyra Therapeutics, Inc. (23.90M), greater than Kronos Bio, Inc. (5.32M), greater than Gossamer Bio, Inc. (331.04M), less than Syndax Pharmaceuticals, Inc. (1.24B), less than Cogent Biosciences, Inc. (929.30M), less than Cullinan Oncology, Inc. (630.54M), greater than Mersana Therapeutics, Inc. (204.64M), less than Immunocore Holdings plc (1.56B), less than Mirum Pharmaceuticals, Inc. (2.24B), greater than Larimar Therapeutics, Inc. (363.34M), less than Cytokinetics, Incorporated (6.54B), less than DICE Therapeutics, Inc. (1.82B), less than Edgewise Therapeutics, Inc. (3.01B), less than Karuna Therapeutics, Inc. (12.43B), less than Dyne Therapeutics, Inc. (2.51B),
Company | Enterprise Value | Market cap |
---|---|---|
4.93B | $5.20B | |
138.26M | $181.50M | |
807.00M | $839.85M | |
1.42B | $1.60B | |
984.10M | $1.02B | |
81.37M | $98.54M | |
23.90M | $12.37M | |
5.32M | $54.49M | |
331.04M | $157.63M | |
1.24B | $1.37B | |
929.30M | $1.01B | |
630.54M | $730.17M | |
204.64M | $252.01M | |
1.56B | $1.61B | |
2.24B | $2.15B | |
363.34M | $393.05M | |
6.54B | $5.79B | |
1.82B | $2.27B | |
3.01B | $3.05B | |
12.43B | $12.60B | |
2.51B | $3.02B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like KalVista Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like KalVista Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is KalVista Pharmaceuticals, Inc.'s Enterprise Value?
What is the highest Enterprise Value for KalVista Pharmaceuticals, Inc. (KALV)?
What is the 3-year average Enterprise Value for KalVista Pharmaceuticals, Inc. (KALV)?
What is the 5-year average Enterprise Value for KalVista Pharmaceuticals, Inc. (KALV)?
How does the current Enterprise Value for KalVista Pharmaceuticals, Inc. (KALV) compare to its historical average?